Polyunsaturated Fatty Acids, Prostaglandins, and Schizophrenia
Polyunsaturated Fatty Acids, Prostaglandins, and Schizophrenia
复制标题
多不饱和脂肪酸、前列腺素和精神分裂症
DOI：
10.1111/j.1749-6632.1989.tb22626.x
复制
发表时间：
1989
影响因子：
5.2
通讯作者：
K. Goetz
中科院分区：
文献类型：
--
作者：
D. Kammen;J. Yao;K. Goetz
精神疾病，特别是精神分裂症，与临床现象有关，可以解释为多不饱和脂肪酸和前列腺素代谢紊乱。以前的研究多不饱和脂肪酸，PG合成，PGE 1受体活性和血小板聚集反应，和临床治疗试验表明，PGE在精神分裂症的病理生理学的作用。由于PGE1活性的降低可能与多巴胺释放的增加有关，因此PGE1缺乏与精神分裂症的多巴胺假说一致。最先进的检测和临床试验方法应阐明PUFA代谢在精神分裂症中的作用。
Psychotic disorders, particularly schizophrenia, are associated with clinical phenomena that can be explained by disturbances in polyunsaturated fatty acid and prostaglandin metabolism. Previous studies of PUFA, PG synthesis, PGE1 receptor activity and aggregation responses in platelets, and clinical treatment trials suggest a role for PGE in the pathophysiology of schizophrenia. Since a decrease in PGE1 activity can be associated with an increase of dopamine release, a deficiency of PGE1 is consistent with the dopamine hypothesis of schizophrenia. State-of-the-art assay and clinical trial methodology should clarify the role of PUFA metabolism in schizophrenia.